UAA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. UAA is holding above key support with bullish moving averages, but momentum is fading (bearish, expanding MACD histogram) while the latest FY2026 Q2 financials show deteriorating revenue, margins, and profitability. With no Intellectia buy signals and earnings (Feb 6, pre-market) as the next major catalyst, the risk/reward at ~6.1–6.2 looks more like a HOLD than an immediate BUY for an impatient investor. A higher-confidence buy setup would require a clean break above ~6.42 (R1) with improving momentum; otherwise the price is vulnerable back toward ~5.76 support.
Trend/levels: Price is hovering near the pivot (6.091) in the 6.1–6.2 area. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been improving. Momentum: MACD histogram is negative (-0.0154) and expanding to the downside, indicating weakening upside momentum despite the bullish MA stack. RSI: RSI_6 ~59.99 (neutral-to-slightly-bullish), not overbought and not giving a strong entry signal. Key levels: Support S1=5.762 (then S2=5.56). Resistance R1=6.42 (then R2=6.622). Near-term upside is likely capped unless it clears 6.42 decisively; failure to hold ~6.09 increases odds of a pullback to ~5.76. Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Hedge funds are buying aggressively: reported buying amount up ~421.57% QoQ, which can support the stock.
Technical structure still constructive: bullish moving-average stack can attract trend followers if momentum turns back up.
Analyst actions include some constructive updates: Citi raised PT to $6.50 (Neutral), UBS maintains Buy with $8 PT, Guggenheim initiated Buy with $6 PT.
Upcoming event catalyst: Earnings on 2026-02-06 (pre-market) could re-rate the stock if guidance/NA stabilization improves.
No supportive news flow in the last week to drive an immediate re-rating.
Latest quarter: FY2026 Q2. Revenue was $1.333B (-4.69% YoY), indicating continued top-line contraction. Gross margin was 47.29% (-4.96% YoY), showing profitability pressure. Net income fell to -$18.81M (down -111.04% YoY) and EPS to -$0.04 (down -110.26% YoY). Overall trend: weakening growth and margins, which makes it harder to justify chasing the stock without a clear inflection signal.
Recent trend: mixed but slightly improving on price targets into late Jan. Citi raised PT to $6.50 (kept Neutral). UBS remains bullish (Buy, PT $8) arguing for stabilization by end of FY26 and growth in FY27. Guggenheim initiated Buy with a $6 PT. On the bearish side, Evercore kept Underperform and cut PT to $4, citing no signs of a turn; Baird stayed Neutral with PT cut to $5.50. Wall Street pros vs cons: Pros: brand asset value and potential multi-year turnaround narrative; some bulls see stabilization leading to FY27 growth. Cons: turnaround timing uncertainty and lack of clear near-term operational inflection; recent quarter showed worsening profitability, supporting the cautious/bearish views.
